Bamco Inc. NY Takes $41.65 Million Position in Heartflow, Inc. $HTFL

Bamco Inc. NY purchased a new stake in shares of Heartflow, Inc. (NASDAQ:HTFL) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 1,237,506 shares of the company’s stock, valued at approximately $41,654,000. Bamco Inc. NY owned about 1.45% of Heartflow at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HTFL. Wellington Management Group LLP acquired a new stake in Heartflow in the third quarter valued at approximately $164,263,000. Baillie Gifford & Co. bought a new position in shares of Heartflow in the 3rd quarter valued at $101,182,000. Schusterman Interests LLC acquired a new stake in shares of Heartflow during the 3rd quarter valued at $65,274,000. Vanguard Group Inc. acquired a new stake in shares of Heartflow during the 3rd quarter valued at $48,871,000. Finally, Capital International Investors bought a new stake in Heartflow during the 3rd quarter worth $43,671,000.

Insider Transactions at Heartflow

In other news, insider Campbell Rogers sold 65,153 shares of the stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $24.49, for a total value of $1,595,596.97. Following the completion of the sale, the insider owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This represents a 46.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John C.M. Farquhar sold 12,837 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $22.66, for a total value of $290,886.42. Following the transaction, the chief executive officer owned 581,450 shares of the company’s stock, valued at $13,175,657. This trade represents a 2.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 2,117,674 shares of company stock worth $59,052,646.

Heartflow Stock Down 1.4%

NASDAQ HTFL opened at $20.49 on Monday. The company has a market capitalization of $1.74 billion and a price-to-earnings ratio of -11.32. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $41.22. The stock has a fifty day simple moving average of $27.66 and a 200 day simple moving average of $30.66.

Analyst Ratings Changes

HTFL has been the subject of several research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Wells Fargo & Company assumed coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $40.00 price objective on shares of Heartflow in a report on Monday, March 9th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $38.50.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.